Moderna Inc [MRNA] stock is trading at $66.83, up 1.64%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MRNA shares have gain 4.19% over the last week, with a monthly amount drifted -13.87%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on September 13, 2024, when Oppenheimer downgraded its rating to a Perform. Previously, JP Morgan downgraded its rating to Underweight on September 13, 2024, and dropped its price target to $70. On September 13, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $65 on the stock. HSBC Securities upgraded its rating to a Hold but stick to its price target of $82 on August 28, 2024. Deutsche Bank upgraded its rating to a Hold and reduced its price target to $80 on August 07, 2024. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on August 05, 2024, and downed its price target to $90. In a note dated February 26, 2024, HSBC Securities downgraded an Reduce rating on this stock and boosted its target price from $75 to $86.
Moderna Inc [MRNA] stock has fluctuated between $62.55 and $170.47 over the past year. Currently, Wall Street analysts expect the stock to reach $148.85 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $66.83 at the most recent close of the market. An investor can expect a potential return of 122.73% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
Moderna Inc [NASDAQ:MRNA] reported sales of 5.04B for the trailing twelve months, which represents a drop of -29.94%. Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at -0.92%, Pretax Profit Margin comes in at -0.86%, and Net Profit Margin reading is -1.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.45 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 65.44 points at the first support level, and at 64.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 68.09, and for the 2nd resistance point, it is at 69.35.
Ratios To Look Out For
For context, Moderna Inc’s Current Ratio is 4.09. Also, the Quick Ratio is 3.92, while the Cash Ratio stands at 1.05. Considering the valuation of this stock, the price to sales ratio is 5.10, the price to book ratio is 2.19.
Transactions by insiders
Recent insider trading involved Klinger Shannon Thyme, Chief Legal Officer, that happened on Sep 09 ’24 when 551.0 shares were sold. Officer, Klinger Shannon Thyme completed a deal on Sep 09 ’24 to buy 551.0 shares. Meanwhile, Chief Legal Officer Klinger Shannon Thyme sold 114.0 shares on Sep 03 ’24.
